Incyte (NASDAQ:INCY) Announces Earnings Results, Beats Expectations By $0.47 EPS

Incyte (NASDAQ:INCY - Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.47, FiscalAI reports. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.23 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. Incyte's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.16 EPS.

Here are the key takeaways from Incyte's conference call:

• Incyte reported strong Q1 2026 results with total revenue of $1.27 billion (+21% y/y) and net sales of $1.10 billion (+20% y/y), and reaffirmed full‑year 2026 net sales guidance of $4.77–$4.94 billion.
• Commercial momentum across the portfolio — Jakafi sales were $758M (+7% y/y) while core ex‑Jakafi sales grew 63% y/y (Opzelura $143M); management expects four near‑term launches (Jakafi XR, Opzelura in Europe, Monjuvi 1L DLBCL, and povorcitinib in HS) to further drive growth.
• Key regulatory and clinical milestones achieved — the FDA accepted the NDA for povorcitinib in moderate‑to‑severe HS, Incyte reported positive phase III vitiligo results supporting a planned 1H‑2027 filing, and Monjuvi first‑line DLBCL global submissions are expected in H1 with approval/launch anticipated in early 2027.
• Pipeline advanced with high‑impact programs — INCA033989 (mutant CALR antibody) had a positive EOP meeting and a phase III ET start is on track mid‑year with MF studies planned, and KRAS G12D INCB161734 initiated a phase III 1L PDAC trial, but these programs remain subject to clinical and regulatory risk.

Incyte Price Performance

NASDAQ:INCY opened at $99.10 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.25. The company has a 50 day moving average price of $95.84 and a 200-day moving average price of $98.76. Incyte has a 1-year low of $57.77 and a 1-year high of $112.29. The firm has a market cap of $19.72 billion, a price-to-earnings ratio of 15.46, a price-to-earnings-growth ratio of 0.77 and a beta of 0.85.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q1 beat — Incyte reported Q1 EPS and revenue above expectations ($1.81 EPS; $1.27B revenue), driven by Jakafi and Opzelura strength, which supports near-term cash flow and investor confidence. Reuters: Incyte beats first-quarter estimates
• Positive Sentiment: Commercial outlook & launches — Management outlined 2026 net sales guidance in the ~$4.77B–$4.94B range and said it’s preparing four product launches over the next 12 months, indicating multiple growth catalysts beyond the core franchise. Seeking Alpha: Incyte outlines 2026 net sales and launches
• Positive Sentiment: Analyst lift — Stifel raised its price target to $123 and maintained a Buy, providing fresh upside thesis and likely supporting demand for the shares. Benzinga: Stifel raises price target
• Positive Sentiment: Investor outreach — Incyte announced presentations at upcoming investor conferences, which can increase visibility and help clarify commercialization plans. Business Wire: Investor conferences
• Neutral Sentiment: Executive change — Incyte appointed Suketu (Suky) Upadhyay as CFO; leadership continuity matters but is not an immediate earnings driver. Yahoo Finance: CFO appointment
• Neutral Sentiment: Clinical readouts — The company posted Phase 3 vitiligo wins for its JAK inhibitor, but competitive pressure from established rivals (e.g., Rinvoq) leaves market-share outcomes uncertain. FierceBiotech: JAK inhibitor results
• Negative Sentiment: Guidance gap — The company’s 2026 revenue range was below some street estimates (consensus higher), which raises questions about how quickly launches will offset patent/market pressures; this likely tempered upside despite the quarter beat. Seeking Alpha: Guidance and sales outlook
• Negative Sentiment: Regulatory/marketing scrutiny — The FDA criticized past promotional claims around Niktimvo, a reputational and compliance risk that could lead to tighter oversight or remediation costs. FiercePharma: FDA criticism

Insider Transactions at Incyte

In related news, insider Pablo J. Cagnoni sold 18,667 shares of the firm's stock in a transaction on Friday, April 17th. The shares were sold at an average price of $96.50, for a total transaction of $1,801,365.50. Following the sale, the insider owned 262,692 shares in the company, valued at approximately $25,349,778. This trade represents a 6.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.80% of the company's stock.

Hedge Funds Weigh In On Incyte

Institutional investors and hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. purchased a new position in Incyte during the fourth quarter worth approximately $65,000. Compound Planning Inc. raised its stake in shares of Incyte by 36.8% during the 4th quarter. Compound Planning Inc. now owns 3,653 shares of the biopharmaceutical company's stock worth $361,000 after buying an additional 983 shares during the period. Invesco Ltd. raised its stake in shares of Incyte by 13.2% during the 4th quarter. Invesco Ltd. now owns 3,473,781 shares of the biopharmaceutical company's stock worth $343,105,000 after buying an additional 405,611 shares during the period. Birchwood Financial Partners Inc. purchased a new position in shares of Incyte during the 4th quarter valued at approximately $115,000. Finally, Corient Private Wealth LLC lifted its position in shares of Incyte by 18.6% during the 4th quarter. Corient Private Wealth LLC now owns 37,827 shares of the biopharmaceutical company's stock valued at $3,736,000 after buying an additional 5,938 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on INCY shares. Morgan Stanley set a $102.00 target price on Incyte in a research note on Wednesday, February 11th. Wall Street Zen downgraded Incyte from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 14th. Weiss Ratings raised Incyte from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, April 1st. Stifel Nicolaus raised their price objective on Incyte from $120.00 to $123.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Piper Sandler lifted their target price on Incyte from $102.00 to $110.00 and gave the stock an "overweight" rating in a report on Friday, February 6th. Ten investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $104.26.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.